EUCTR2004-000022-75-LV进行中（未招募）不适用
Irbesartan versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Hypertensive Albuminuria in Subjects at Elevated Cardiovascular Risk - IMPROVE
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 615
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •males and females 55 years of age and over
- •documented histroy of hypertension
- •subjects with demonstrated albuminuria as measured using a urine dipstick
- •subjects with one or more additional cardiovascular risk factors defined as: diabetes, advanced coronary artery disease defined as previous myocardial infarction, unstable angina, or angina pectoris with a positive stress test or at least two-vessel disease demonstarted on a coronary angiogram; peripheral vascular disease- angiographically proven or prior vascular surgery, amputation or intermittent claudication with a ankle/ brachial pressure index of < 0.9; cerebrovascular accident occurring greater tham 3 months prior to the screening visit; subjects currently on a stable dose of a ACE-I therapy equivalent to 5mg or more of ramipril for a minimum of 2 months prior to their screening/ enrollment visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk - IMPROVEAlbuminuria in hypertensive subjects at increased cardiovascular risk.EUCTR2004-000022-75-LTBristol-Myers Squibb International Corporation615
进行中（未招募）
1 期
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Subjects at Elevated Cardiovascular Risk - IMPROVEEUCTR2004-000022-75-ESBristol-Myers Squibb International Corporation615
进行中（未招募）
不适用
Irbesartan Versus Placebo in Combination with Standard Cardiovascular Protection ACE-I Therapy with Ramipril for the Treatment of Albuminuria in Hypertensive Subjects at Elevated Cardiovascular Risk.EUCTR2004-000022-75-ITBRISTOL-M.SQUIBB600
招募中
不适用
Effect of on combination therapy with irbesartan and amlodipine besilate on clinical blood pressure, home blood pressure and blood pressure variability in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD G1-G4)JPRN-UMIN000013213Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine30
已完成
4 期
Effects of the combination therapy of irbesartan and indapamide in chronik kidney disease with hypertensiochronick kidney disease with hypertensionJPRN-UMIN000010787Division of Nephrology, Department of Internal medicine, Jichi Medical University30